Evidence map›Paper›PMID 41243072›Full record

ArticleJournal of thrombosis and thrombolysis2026

Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scale.

Nikolay A Shamalov, Zhanna Yu Chefranova, Elena B Yarovaya, Vladimir A Kutsenko, Natalya A Marskaya, Andrey M Semenov, Mikhail P Semenov, Sergey V Ivanov, Yulia A Romashova, Sergey S Markin

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06707987 (An Open, Prospective, Non-interventional, Multicentre, Controlled Study of Safety and Efficacy of the Thrombolysis With the Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06707987 completednot on this map

An Open, Prospective, Non-interventional, Multicentre, Controlled Study of Safety and Efficacy of the Thrombolysis With the Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke (FORPI Registry)

Typeobservational_patient_registrySponsorSupergene, LLCRan2021 to 2025Enrolled23,250ConditionsAcute Ischemic StrokeArmsNon-immunogenic staphylokinase
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nikolay A ShamalovFederal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency, Moscow, Russia.ORCID http://orcid.org/0000-0001-6250-0762
Zhanna Yu ChefranovaBelgorod State National Research University, Belgorod, Russia.ORCID http://orcid.org/0000-0002-2106-7461
Elena B YarovayaNational Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia.ORCID http://orcid.org/0000-0002-6615-4315
Vladimir A KutsenkoNational Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia.ORCID http://orcid.org/0000-0001-9844-3122
Natalya A MarskayaFederal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency, Moscow, Russia.ORCID http://orcid.org/0000-0002-0789-4823
Andrey M SemenovPatrice Lumumba Peoples' Friendship University of Russia (RUDN), Moscow, Russia.ORCID http://orcid.org/0000-0003-1247-4978
Mikhail P SemenovPatrice Lumumba Peoples' Friendship University of Russia (RUDN), Moscow, Russia.ORCID http://orcid.org/0000-0002-6877-4817
Sergey V IvanovInstitute of Biomedical Chemistry, Moscow, Russia.ORCID http://orcid.org/0000-0003-0438-9108
Yulia A RomashovaInstitute of Biomedical Chemistry, Moscow, Russia.ORCID http://orcid.org/0000-0001-9580-0251
Sergey S MarkinInstitute of Biomedical Chemistry, Moscow, Russia. phospholipovit@ibmc.msk.ru.ORCID http://orcid.org/0000-0002-0242-0282

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2024-643
6 · The paper itself

Abstract

This study aimed to assess the prognostic value of the THRIVE scale in patients aged ≥ 60 years with acute ischemic stroke (AIS) after intravenous thrombolysis with the non-immunogenic staphylokinase compared with alteplase. The post-hoc analysis of FRIDA trial results was performed and enrolled patients aged ≥ 60 years were divided into two groups in accordance with the modified Rankin scale (mRS) score on day 90: good-outcome (mRS 0-2) and poor-outcome (mRS 3-6) groups. The receiver operating characteristic (ROC) curves were compared using Delong test. For all-cause mortality on day 90 the predicted AUC value by the THRIVE scale was 0.8 (0.71-0.9) in the non-immunogenic staphylokinase group and 0.76 (0.66-0.87) in the alteplase group (p = 0.57). For poor outcome, AUC value was 0.73 (0.64-0.82) in the non-immunogenic staphylokinase group and 0.79 (0.71-0.87) in alteplase group (p = 0.36). Thus, our study confirmed the prognostic value of the THRIVE scale to predict the outcomes of the patients aged ≥ 60 years treated with the non-immunogenic staphylokinase.

Indexed as

Ischemic StrokeMetalloendopeptidasesThrombolytic TherapyAdministration, IntravenousAgedFemaleFibrinolytic AgentsHumansMaleMiddle AgedPrognosisTissue Plasminogen ActivatorTreatment OutcomeauR protein, Staphylococcus aureusFibrinolytic AgentsMetalloendopeptidasesTissue Plasminogen ActivatorAcute ischemic strokeNon-immunogenic staphylokinaseThrombolysis

Identifiers

PMID41243072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.